Hypertonic Otoprotective Composition for Platinum-Induced Hearing Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Platinum-based antineoplastic agents cause hearing loss in patients undergoing chemotherapy, necessitating the development of otoprotective compositions to prevent or mitigate this ototoxicity.
Innovation Solution
Hypertonic pharmaceutical compositions containing anti-platinum chemoprotectant agents and gelling agents, administered via intratympanic or transtympanic routes, to protect against platinum-induced ototoxicity by increasing bioavailability and retention at the round window.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platinum-based antineoplastic agents are administered to treat cancer, then therapeutic efficacy is improved, but ototoxicity (hearing loss) increases
Solution Approach 1:
An anti-platinum chemoprotectant agent is introduced as an intermediary substance that selectively binds to platinum-based antineoplastic agents in the inner ear, preventing them from damaging auditory structures. The chemoprotectant acts as a mediator that neutralizes the harmful effects of platinum agents locally at the round window without significantly interfering with their systemic anticancer activity.
Solution Approach 2:
The chemoprotectant is administered via intratympanic injection to achieve high local concentration at the round window and inner ear, creating a localized protective effect. This local administration strategy ensures that the chemoprotectant is concentrated where it is needed most (in the inner ear) while minimizing systemic interactions that could reduce cancer treatment efficacy.
2Quantity of substance
If intratympanic administration is used to deliver chemoprotectant, then bioavailability at round window is improved, but administration complexity increases
Solution Approach 1:
The chemoprotectant is administered via intratympanic injection before or concurrent with platinum-based chemotherapy, establishing protective coverage in the inner ear in advance. This preliminary local administration ensures that the chemoprotectant is already present at therapeutic concentrations when the platinum agent reaches the inner ear, maximizing protective efficacy.
3Reliability
If high concentration of chemoprotectant is used, then otoprotective effect is improved, but risk of adverse effects increases
Solution Approach 1:
The chemoprotectant is administered via intratympanic injection to achieve high local concentration at the round window and inner ear, creating a localized protective effect. This local administration strategy ensures that the chemoprotectant is concentrated where it is needed most (in the inner ear) while minimizing systemic exposure and associated adverse effects.
Solution Approach 2:
The chemoprotectant is administered before or concurrent with platinum-based chemotherapy to preemptively block the ototoxic effects. By establishing protective binding sites in the inner ear in advance, the chemoprotectant prevents platinum from causing damage without requiring excessively high doses that would increase systemic adverse effects.
Data Source
AI summary
Hypertonic pharmaceutical compositions are disclosed. The hypertonic pharmaceutical compositions contain an anti-platinum chemoprotectant agent and a gelling agent. Also disclosed are methods of medical use of the hypertonic pharmaceutical compositions.